Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, and its news flow reflects active clinical development, collaborations and capital markets activity. Company updates frequently highlight progress with cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and certain lymphomas, as well as broader pipeline and platform achievements.
News for C4 Therapeutics often centers on clinical data milestones, such as Phase 1 results for cemsidomide in combination with dexamethasone, acceptance of data for oral presentation at scientific meetings, and plans for registrational trials like the Phase 2 MOMENTUM study. Releases also cover developments in non-Hodgkins lymphoma cohorts and updates on other degrader programs, including CFT8919 for EGFR-mutant non-small cell lung cancer and CFT1946 for BRAF V600 mutant solid tumors.
Investors following CCCC news will also see collaboration announcements and research milestones. Examples include the clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide with elranatamab in multiple myeloma, milestone achievements in partnerships with Biogen, Roche and Merck KGaA, Darmstadt, Germany, and regulatory steps such as IND acceptance for BIIB142, an IRAK4 degrader designed by C4 Therapeutics.
Financial and corporate updates are another key news category. The company regularly reports quarterly financial results, cash runway guidance, equity offerings and changes to its capital structure via press releases and Form 8-K filings. For readers tracking CCCC, this news page aggregates these clinical, scientific, collaboration and financing updates in one place, making it easier to monitor how C4 Therapeutics is advancing its targeted protein degradation pipeline over time.
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical innovator, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 a.m. ET. C4T specializes in a unique class of small-molecule drugs aimed at selectively degrading disease-causing proteins, targeting conditions like cancer and neurodegenerative diseases. A live webcast of the presentation will be available on their website, with a replay archived for two weeks. This targeted protein degradation approach offers potential advantages over traditional therapies, including reduced drug resistance and fewer side effects.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has reinforced its leadership team with key appointments, including Andrew Hirsch as CEO. The company successfully completed an upsized IPO in October 2020, raising $209.8 million, extending its cash runway into the second half of 2023. For Q3 2020, C4T reported revenues of $8.4 million, up from $5.4 million in Q3 2019, driven by collaboration agreements. However, R&D expenses surged to $23.9 million, resulting in a net loss of $21.8 million. The company anticipates an IND submission for its lead candidate, CFT7455, by the end of 2020.
On October 14-15, 2020, C4 Therapeutics (Nasdaq: CCCC) will present at the 3rd Annual Targeted Protein Degradation Summit. Dr. Rhamy Zeid will discuss the use of C4T’s TORPEDO™ platform for developing selective protein degraders, focusing on CFT8634 for synovial sarcoma. Dr. Stewart Fisher will lead a roundtable on the challenges and opportunities in drug discovery. The company aims to optimize protein degradation to provide new treatments for cancer and neurodegenerative diseases, showcasing its innovative approach in the biopharmaceutical industry.
C4 Therapeutics, a biopharmaceutical company focused on developing small-molecule drugs to degrade disease-causing proteins, announced the successful closing of its initial public offering (IPO) on October 6, 2020. The company sold 11.04 million shares, including 1.44 million additional shares purchased through underwriters' options, priced at $19.00 each. This resulted in gross proceeds of approximately $209.76 million, before expenses. The IPO is managed by Jefferies, Evercore ISI, BMO Capital Markets, and UBS Investment Bank.
C4 Therapeutics (Nasdaq: CCCC) has priced its upsized initial public offering at $19 per share, offering 9.6 million shares for gross proceeds of approximately $182.4 million. The offering is scheduled to begin trading on the Nasdaq Global Market on October 2, 2020, and is expected to close on October 6, 2020, pending customary closing conditions. The company has also granted underwriters a 30-day option to purchase an additional 1.44 million shares. C4T focuses on developing small-molecule drugs to selectively degrade disease-causing proteins for cancer and neurodegenerative conditions.